Remembering the host in tuberculosis drug development

Daniel J. Frank, David J. Horne, Noton K. Dutta, Moagi Tube Shaku, Rajhmun Madensein, Thomas R. Hawn, Adrie J.C. Steyn, Petros C. Karakousis, Bavesh Davandra Kana, Graeme Meintjes, Barbara Laughon, Zaid Tanvir

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tuberculosis Drug Development in Lucca, Italy in June 2017, titled “Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB.” In this review, we will highlight recent data regarding drugs, pathways, and concepts that are important for successful development of HDTs for TB.

Original languageEnglish (US)
Pages (from-to)1518-1524
Number of pages7
JournalJournal of Infectious Diseases
Issue number10
StatePublished - May 1 2019


  • Drug development
  • Host-directed therapy
  • Macrophage
  • Meningitis
  • Tuberculosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Remembering the host in tuberculosis drug development'. Together they form a unique fingerprint.

Cite this